Pfizer and BioNTech, are adjusting to decreasing demand for Covid-19 treatments. Image credit: Shutterstock/Marco Lazzarini.

Hot on the heels of Pfizer recording a $5.5bn non-cash charge due to Covid product write-offs, BioNTech, a partner for the Comirnaty vaccine, has said it also expects to experience revenue drops.

In a  13 October announcement, Pfizer said the US Government will return nearly eight million courses of the company’s Covid-19 antiviral pill Paxlovid (nirmatrelvir/ritonavir). The move, which is via a non-cash return, means Pfizer has reduced its 2023 revenue expectations for Paxlovid by around $7bn, which includes a non-cash $4.2bn revenue reversal.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Shares in Pfizer were down by 2.5% when the market closed on 13 October compared to the pre-announcement market opening.

Citing lower-than-expected utilisation of its Covid products, Pfizer stated that inventory write-offs for Paxlovid contributed $4.6bn to the $5.5bn charge while Comirnaty – co-developed with BioNTech – made up the remaining $900m.

In a 16 October press release, BioNTech said it will feel the effects of the write-off for the mRNA vaccine for which it has a profit-sharing agreement. Pfizer has slashed 2023 revenue expectations for the Comirnaty by $2bn; BioNTech said it expects its full-year revenues to be reduced as a result. BioNTech will publish its Q3 earnings on 6 November.

Blaming solely the lower demand for its Covid products, Pfizer also announced it is dropping its full-year revenue guidance to a range of $58bn-$61bn, down from a previous estimation of $67bn-$70bn.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In a bid to regain revenue stability, Pfizer said it is planning to save around $3.5bn by cutting jobs and expenses. The company aims to raise $1bn by the end of 2023, with the remaining savings completed in 2024.

The write-offs do not affect the Pfizer/BioNTech Comirnaty vaccine adapted to XBB.1.5, a new subtype of the Omicron variant. Known as Comirnaty Omicron XBB.1.5, the vaccine was approved for marketing in Europe in August 2023 and approved by the FDA in September 2023.

Pfizer chairman and CEO Dr Albert Bourla said in a company statement: “We expect additional clarification on global vaccination and treatment rates by the end of the year, which we expect will be a good predictor of utilisation in future years.”